This restriction allows CAR-NKT cells to be engineered with CARs targeting TAAs and to harness their natural ability to detect lipids presented by CD1d, broadening their effectiveness against tumours that escape standard MHC-based immunity. The gene discussed is CD1D; the disease is neoplasm.